The results showed that DOV 102,677, the triple monoamine uptake inhibitor, dose-dependently reduced the voluntary consumption of ethanol by up to 71.2% over the course of the treatment period
This leads to muscle loss, weakness, slower metabolism, and poorer health
however, differences in injection frequency, dose escalation, and device design meant that investigators were not blinded to which active treatment participants received [1]
Is this product certified for food use
5-Amino-1MQ Dosage Protocol Guide: Comparative Approaches Research institutions employ varied 5-amino-1mq dosage protocols depending on study design, outcome measures, and population characteristics
(1995) Structure-activity relationships of melanocortin peptide agonists Annals of the New York Academy of Sciences, 780:51-62